Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens

Selim HMRM 1 , Gomaa FAM 2 , Alshahrani MY 3 , Morgan RN 4 , Aboshanab KM 5

Affiliations 

  • 1 Department of Pharmaceutical Sciences, Faculty of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia
  • 2 Department of Pharmacognosy and Medicinal Herbs, Faculty of Pharmacy, Al-Baha University, Al-Baha, Saudi Arabia
  • 3 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
  • 4 National Centre for Radiation Research and Technology (NCRRT), Drug Radiation Research Department, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt
  • 5 Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
Ther Deliv, 2024 Nov 15.
PMID: 39545771 DOI: 10.1080/20415990.2024.2426824

Abstract

The ongoing global health crisis caused by multidrug-resistant (MDR) bacteria necessitates quick interventions to introduce new management strategies for MDR-associated infections and antimicrobial agents' resistance. Phage therapy emerges as an antibiotic substitute for its high specificity, efficacy, and safety profiles in treating MDR-associated infections. Various in vitro and in vivo studies denoted their eminent bactericidal and anti-biofilm potential. This review addresses the latest developments in phage therapy regarding their attack strategies, formulations, and administration routes. It additionally discusses and elaborates on the status of phage therapy undergoing clinical trials, and the challenges encountered in their usage, and explores prospects in phage therapy research and application.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications